{"brief_title": "A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen", "brief_summary": "The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.", "condition": ["Chronic Hepatitis B"], "intervention_type": ["Drug"], "intervention_name": ["Entecavir"], "criteria": "- Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection; - Documentation of positive Hepatitis B e antigen (HBeAg) status.; - The absence of coinfection with immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV); - The absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease; - Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis, Chronic", "Hepatitis B", "Hepatitis B, Chronic", "Entecavir"], "id": "NCT00035633"}